Atlizumab

Anti-IL-6 receptor antibody — Chugai, Anti-interleukin-6 receptor antibody — Chugai, MRA — Chugai

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Nishimoto N, Yoshizaki K, Miyasaka N, et al. A multi-center, randomized, double-blind, placebo-controlled trial of humanized anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum 2002 Sep; 46Suppl.: 559
Google Scholar
Choy EHS, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002 Dec; 46: 3143–50
Article PubMed CAS Google Scholar
Maini R, Charisma Study Group. A double-blind, randomised, parallel group, controlled, dose ranging study of the safety, tolerability, pharmacokinetics and efficacy of repeat doses of MRA given alone or in combination with methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003 Jul; 62Suppl. 1: 64
Google Scholar
Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000 May; 6(5): 583–8
Article PubMed CAS Google Scholar
Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000 Jan 1; 95(1): 56–61
PubMed CAS Google Scholar

Atlizumab. BioDrugs 17, 369–372 (2003). https://doi.org/10.2165/00063030-200317050-00006

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.